Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

724
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
724
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

134
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
134
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

648
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
648
Drug Therapy01:28

Drug Therapy

364
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
364
Bipolar Disorder01:30

Bipolar Disorder

1.3K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.3K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.7K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Prognostic Relevance of Cycle Pattern Recognition in Bipolar Disorder: A Further Step Toward Personalised Treatment Pathways?

Current neuropharmacology·2026
Same author

Autistic Trait Profiles Across Mood and Psychotic Spectrum Disorders: A Transdiagnostic Outpatient Study.

Journal of clinical medicine·2026
Same author

Dopaminergic dysfunction in substance-related and behavioral addictions: Evidence from SPECT imaging in alcohol and gambling disorders.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Brain Morphology Mediators of the Association of Childhood Trauma With Bipolar Disorder: An International ENIGMA Bipolar Disorder Working Group Study.

JAMA psychiatry·2026
Same author

Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.

Journal of clinical medicine·2026
Same author

Disordered Minds, Disordered Meals: When Emotions Masquerade as Hunger in Eating Disorders-A Systematic Review.

Nutrients·2026
Same journal

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Drugs in R&D·2026
Same journal

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.

Drugs in R&D·2026
Same journal

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

Drugs in R&D·2026
Same journal

Ustekinumab in the Management of Perianal Fistulizing Crohn's Disease: Current Evidence and Practical Strategies.

Drugs in R&D·2026
Same journal

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.

Drugs in R&D·2026
Same journal

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.

Drugs in R&D·2026
See all related articles

Related Experiment Video

Updated: Mar 13, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations.

Paolo Girardi1,2,3, Roberto Brugnoli4,5, Giovanni Manfredi5,6

  • 1Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), School of Medicine and Psychology, Sapienza University of Rome, Rome, Italy. paolo.girardi@uniroma1.it.

Drugs in R&D
|October 23, 2016
PubMed
Summary
This summary is machine-generated.

Lithium remains a vital mood stabilizer for bipolar disorder (BD). Prolonged-release (PR) lithium offers consistent levels, fewer side effects, and better adherence compared to immediate-release (IR) formulations.

More Related Videos

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.0K
The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

83.9K

Related Experiment Videos

Last Updated: Mar 13, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
09:30

Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil

Published on: October 4, 2016

23.0K
The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

83.9K

Area of Science:

  • Pharmacology and Psychiatry
  • Neuroscience

Background:

  • Lithium is a long-standing, first-line mood stabilizer for bipolar disorder (BD).
  • Despite its efficacy, lithium use has seen some decline, yet it remains crucial for managing manic and depressive episodes in BD.

Purpose of the Study:

  • To review the pharmacology and clinical profile of lithium in bipolar disorder management.
  • To highlight the advantages of prolonged-release (PR) lithium formulations over immediate-release (IR) formulations.

Main Methods:

  • Literature search of PubMed using terms like 'lithium', 'prolonged-release', 'bipolar disorder', 'adherence', and 'compliance'.
  • Inclusion of relevant pharmacodynamic and pharmacokinetic data.

Main Results:

  • Lithium is effective for acute mania, BD prophylaxis, and suicide risk reduction in BD patients.
  • PR lithium formulations demonstrate consistent serum concentrations, reduced adverse events, and improved patient adherence.
  • Lithium requires careful monitoring to prevent toxicity.

Conclusions:

  • PR lithium formulations offer potential advantages over IR formulations in bipolar disorder management.
  • PR lithium may lead to fewer adverse events and improved therapeutic adherence.
  • Lithium, particularly PR formulations, remains a valuable tool in bipolar disorder treatment.